Your browser is no longer supported. Please, upgrade your browser.
Karyopharm Therapeutics Inc.
Index- P/E- EPS (ttm)-2.76 Insider Own9.66% Shs Outstand75.46M Perf Week3.11%
Market Cap583.99M Forward P/E- EPS next Y-2.19 Insider Trans-0.01% Shs Float68.25M Perf Month24.51%
Income-206.20M PEG- EPS next Q-0.49 Inst Own78.10% Short Float17.76% Perf Quarter53.90%
Sales118.70M P/S4.92 EPS this Y15.40% Inst Trans0.98% Short Ratio5.27 Perf Half Y-6.33%
Book/sh-1.67 P/B- EPS next Y27.60% ROA-73.10% Target Price14.00 Perf Year-45.13%
Cash/sh2.90 P/C2.86 EPS next 5Y- ROE416.20% 52W Range4.42 - 17.39 Perf YTD28.77%
Dividend- P/FCF- EPS past 5Y3.90% ROI-71.30% 52W High-52.39% Beta-0.16
Dividend %- Quick Ratio3.50 Sales past 5Y236.60% Gross Margin96.90% 52W Low87.33% ATR0.57
Employees432 Current Ratio3.50 Sales Q/Q77.00% Oper. Margin- RSI (14)60.85 Volatility8.58% 7.69%
OptionableYes Debt/Eq- EPS Q/Q5.70% Profit Margin- Rel Volume1.05 Prev Close7.73
ShortableYes LT Debt/Eq- EarningsNov 03 BMO Payout- Avg Volume2.30M Price8.28
Recom2.40 SMA2012.28% SMA5013.98% SMA2007.94% Volume2,408,037 Change7.12%
Nov-19-21Resumed Morgan Stanley Equal-Weight $27 → $10
Aug-06-21Downgrade SVB Leerink Outperform → Mkt Perform $6
Aug-06-21Downgrade RBC Capital Mkts Outperform → Sector Perform $17 → $8
Aug-06-21Downgrade JP Morgan Overweight → Neutral
Jul-02-20Initiated Morgan Stanley Overweight $34
Mar-04-20Initiated Barclays Overweight $30
Jan-17-20Downgrade Wedbush Outperform → Neutral
Jul-23-19Upgrade JP Morgan Neutral → Overweight $8 → $16
Jul-05-19Reiterated Robert W. Baird Outperform $15 → $25
Jul-05-19Reiterated H.C. Wainwright Buy $29 → $32
Mar-01-19Downgrade JP Morgan Overweight → Neutral $21 → $7
Feb-28-19Reiterated BofA/Merrill Underperform $15 → $5
Feb-27-19Downgrade BofA/Merrill Neutral → Underperform $15 → $5
Jan-03-19Upgrade BofA/Merrill Underperform → Neutral
Dec-03-18Initiated B. Riley FBR Buy $23
Nov-09-18Upgrade Wedbush Neutral → Outperform $19
May-24-18Downgrade Wedbush Outperform → Neutral $20 → $19
Apr-02-18Resumed Leerink Partners Outperform $19
Nov-15-17Resumed H.C. Wainwright Buy $23
Sep-15-17Initiated RBC Capital Mkts Outperform $14
Jan-21-22 07:00AM  
Jan-10-22 07:05AM  
Jan-04-22 07:00AM  
Jan-03-22 04:05PM  
Dec-21-21 08:39PM  
Dec-17-21 08:37AM  
Dec-11-21 12:00PM  
Dec-06-21 04:05PM  
Dec-02-21 07:00AM  
Dec-01-21 04:05PM  
Nov-29-21 09:00AM  
Nov-11-21 07:00AM  
Nov-04-21 10:30AM  
Nov-03-21 03:01PM  
Nov-01-21 04:05PM  
Oct-27-21 07:00AM  
Oct-25-21 03:01PM  
Oct-23-21 06:08AM  
Oct-21-21 08:00AM  
Oct-01-21 04:05PM  
Sep-07-21 07:00AM  
Sep-01-21 07:00AM  
Aug-20-21 11:16AM  
Aug-13-21 09:16AM  
Aug-07-21 03:46AM  
Aug-05-21 08:00PM  
Aug-03-21 07:00AM  
Aug-02-21 07:00AM  
Jul-29-21 07:00AM  
Jul-28-21 07:00AM  
Jul-27-21 03:03PM  
Jul-20-21 12:43AM  
Jul-01-21 08:00AM  
Jun-24-21 07:00AM  
Jun-09-21 01:49PM  
Jun-08-21 08:00PM  
Jun-03-21 07:00AM  
Jun-02-21 07:00AM  
Jun-01-21 04:01PM  
May-26-21 08:00AM  
May-19-21 05:01PM  
May-09-21 03:55AM  
May-04-21 08:00AM  
May-03-21 04:30PM  
Apr-28-21 07:00AM  
Apr-26-21 07:00AM  
Apr-19-21 07:00AM  
Apr-14-21 03:33AM  
Apr-06-21 06:19AM  
Apr-01-21 08:00AM  
Mar-29-21 02:27PM  
Mar-01-21 04:05PM  
Feb-17-21 04:05PM  
Feb-13-21 02:04AM  
Feb-12-21 10:50PM  
Feb-11-21 02:30PM  
Feb-04-21 09:00AM  
Feb-01-21 04:05PM  
Jan-29-21 10:50PM  
Jan-11-21 08:00AM  
Jan-04-21 04:05PM  
Jan-03-21 07:00PM  
Dec-21-20 09:29AM  
Dec-20-20 07:00PM  
Dec-18-20 10:50PM  
Dec-15-20 07:00AM  
Dec-14-20 02:14AM  
Dec-11-20 11:08AM  
Dec-07-20 04:05PM  
Dec-01-20 04:05PM  
Nov-30-20 03:48AM  
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company's lead compound, XPOVIO (selinexor), is approved in the U.S. in various hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Its NEXPOVIO (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition, the company's SINE compounds also show biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Further, it also has various investigational programs in clinical or preclinical development. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mitchener StephenSVP, Chief Business OfficerDec 02Sale6.694993,3383,296Dec 03 06:17 PM
Mitchener StephenSVP, Chief Business OfficerJun 02Sale9.295284,9052,472Jun 03 04:06 PM
Shah JatinEVP, Chief Medical OfficerMay 07Buy8.6023,250199,992131,802May 11 08:58 AM
BOHLIN GAREN GDirectorMay 06Buy7.824,00031,2804,000May 10 07:57 PM
Shacham SharonPresident & CSOMar 18Sale12.394,00049,553714,826Mar 23 07:50 AM
Kauffman MichaelChief Executive OfficerMar 18Sale12.394,00049,553714,826Mar 23 07:48 AM
Frenkel RanEVP, Chief Dev. OfficerFeb 18Sale14.832,88742,81846,126Feb 22 08:11 PM
Shah JatinEVP, Chief Medical OfficerFeb 18Sale14.831,18617,59051,791Feb 22 08:12 PM
Shacham SharonPresident & CSOFeb 18Sale14.839,495140,822575,126Feb 22 08:10 PM
Shacham SharonPresident & CSOFeb 18Sale14.839,495140,822776,452Feb 22 08:10 PM
Kauffman MichaelChief Executive OfficerFeb 18Sale14.839,495140,822776,452Feb 22 08:09 PM
Kauffman MichaelChief Executive OfficerFeb 18Sale14.839,495140,822575,126Feb 22 08:09 PM
Lewis TanyaEVP, Chief Reg. AffairsFeb 11Sale15.522,04631,7524,143Feb 17 06:49 PM
Shah JatinEVP, Chief Medical OfficerFeb 11Sale15.521,74827,12748,127Feb 17 06:48 PM
Frenkel RanEVP, Chief Dev. OfficerFeb 11Sale15.522,04631,75239,338Feb 17 06:47 PM
Shacham SharonPresident & CSOFeb 11Sale15.526,601102,441562,821Feb 17 06:45 PM
Shacham SharonPresident & CSOFeb 11Sale15.526,642103,077764,147Feb 17 06:45 PM
Mason MichaelSVP, CFO & TreasurerFeb 11Sale15.522,85844,3545,292Feb 17 06:46 PM
Kauffman MichaelChief Executive OfficerFeb 11Sale15.526,642103,077764,147Feb 17 06:44 PM
Kauffman MichaelChief Executive OfficerFeb 11Sale15.526,601102,441562,821Feb 17 06:44 PM